Tyrosine kinase inhibitor as adjuvant treatment of renal cell carcinoma: 1 versus 3

被引：0
|
作者：
Penel, Nicolas [1 ]
机构：
[1] Ctr Oscar Lambret, Dept Cancerol Gen, 3 Rue F Combemale, F-59020 Lille, France
来源：
BULLETIN DU CANCER | 2017年 / 104卷 / 09期
关键词：
Renal cell carcinoma; Adjuvant; Pazopanib; NEPHRECTOMY;
D O I：
10.1016/j.bulcan.2017.06.015
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：705 / 706
页数：2
相关论文
共 50 条
  • [41] Treatment of advanced renal cell carcinoma after tyrosine kinase inhibitor therapy: first experiences with Everolimus (Afinitor®) in practice
    Johannsen, M.
    Kempkensteffen, C.
    Miller, K.
    Weikert, S.
    ONKOLOGIE, 2010, 33 : 90 - 90
  • [42] Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy
    Laukhtina, Ekaterina
    Quhal, Fahad
    Mori, Keiichiro
    Motlagh, Reza Sari
    Rajwa, Pawel
    Yanagisawa, Takafumi
    Mostafaei, Hadi
    Konig, Frederik
    Aydh, Abdulmajeed
    Pradere, Benjamin
    Enikeev, Dmitry
    Karakiewicz, Pierre, I
    Schmidinger, Manuela
    Shariat, Shahrokh F.
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (01): : 120 - 124
  • [43] Determinants of neoadjuvant immune checkpoint inhibitor plus tyrosine kinase inhibitor therapy response in renal cell carcinoma
    Gu, L.
    Liang, Q.
    Zhang, X.
    Wang, B.
    ANNALS OF ONCOLOGY, 2024, 35 : S1507 - S1507
  • [44] Novel tyrosine kinase inhibitors for renal cell carcinoma
    Dorff, Tanya B.
    Pal, Sumanta K.
    Quinn, David I.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2014, 7 (01) : 67 - 73
  • [45] Discontinuation of the Tyrosine Kinase Inhibitor Sunitinib in Patients with Metastatic Renal Cell Carcinoma: A Case Series
    Neuhaus, Thomas
    Luyken, Joachim
    Stier, Sebastian
    UROLOGY JOURNAL, 2014, 11 (02) : 1494 - 1498
  • [46] TRIBE; Tyrosine kinase inhibitor therapy in renal-cell carcinoma: Immune biomarker evaluation
    Villa, S.
    Pillai, M.
    Graham, D.
    Kilgour, E.
    Overton, N.
    Vasudev, N.
    Hughes, A.
    Walker, A.
    Dransfield, S.
    Thistlethwaite, F.
    ANNALS OF ONCOLOGY, 2018, 29 : 20 - 20
  • [47] PSMA PET/CT for tyrosine-kinase inhibitor monitoring in metastatic renal cell carcinoma
    Mittlmeier, L. M.
    Unterrainer, M.
    Todica, A.
    Cyran, C. C.
    Rodler, S.
    Bartenstein, P.
    Stief, C. G.
    Ilhan, H.
    Staehler, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (09) : 2216 - 2217
  • [48] Tyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in Renal Cell Carcinoma Patients
    Tullemans, Bibian M. E.
    Nagy, Magdolna
    Sabrkhany, Siamack
    Griffioen, Arjan W.
    Egbrink, Mirjam G. A. Oude
    Aarts, Maureen
    Heemskerk, Johan W. M.
    Kuijpers, Marijke J. E.
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2018, 5
  • [49] MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma
    Kovacova, Julia
    Poprach, Alexandr
    Buchler, Tomas
    Cho, William C.
    Slaby, Ondrej
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2018, 56 (09) : 1426 - 1431
  • [50] PSMA PET/CT for tyrosine-kinase inhibitor monitoring in metastatic renal cell carcinoma
    L. M. Mittlmeier
    M. Unterrainer
    A. Todica
    C. C. Cyran
    S. Rodler
    P. Bartenstein
    C. G. Stief
    H. Ilhan
    M. Staehler
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 2216 - 2217
12345